FDA mRNA-1083 coverage for business development, investment, and market access teams
Latest on mRNA-1083
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.
Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses
Moderna's mRNA-1083 posted positive Phase 3 results in adults 50 and older, meeting primary endpoints with stronger immune responses against influenza and SARS-CoV-2 than licensed comparators. The readout strengthens the case for a combined flu-COVID vaccine, but regulatory questions about the separate flu vaccine filing remain relevant for BD teams and investors.